HALO
Halozyme Therapeutics Inc
108.30$
-1.4%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -63.1% | -27.5% | -34.3% | 42.3% | -32.6% | -43.6% | 20.7% | 67.5% | 36.4% | 46.9% | 47.2% | 46.7% | |
| 2.3% | 1.2% | 1.6% | 0.7% | 1.6% | 2.1% | 1.2% | 0.7% | 8.7% | 10.2% | 8.7% | 6.3% | |
| 20.3% | 15.4% | 17.4% | 9.7% | 23.5% | 17.7% | 6.4% | 4.7% | 3.7% | 4.4% | 4.3% | 3.7% | |
| 20.6% | 16.1% | 22.7% | 14.7% | 23.5% | 18.4% | 6.1% | -25.6% | 10.2% | – | – | – | |
| 0.1% | -21.8% | 11.6% | 6.5% | -3.9% | -25.8% | -40.5% | 0.8% | -16.7% | -4.7% | -13.4% | -10.9% | |
| 1.8% | 1.7% | 2.1% | 0.4% | 3.1% | 2.1% | 0.9% | 0.3% | 0.7% | 1.8% | 1.1% | 0.5% | |
| -43.7% | 4.4% | -52.3% | -51.7% | 1.6% | -2.8% | 29.3% | -91.6% | -73.8% | -11.7% | -25.9% | -39.1% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | 7.3% | 23.7% | 2.8% | – | 1.6% | – | – | |
| 152.0% | 9.7% | 1.3% | 46.6% | 9.0% | -102.0% | -56.1% | -79.0% | -30.3% | -48.5% | -24.6% | -24.5% | |
| 197.5% | 110.1% | 101.4% | -5.1% | -51.0% | 173.0% | -7.3% | 93.8% | 93.5% | -1.6% | 0.0% | 32.3% | |
| 152.0% | 9.7% | 102.7% | 41.6% | -42.0% | 78.2% | -39.7% | 17.6% | 54.9% | -49.2% | -21.6% | -6.1% | |
| 45.2% | -13.4% | 16.0% | 32.2% | -73.0% | 31.8% | 10.3% | -6.5% | 17.5% | -14.0% | -0.2% | 1.5% | |
| -64.9% | -29.2% | -36.5% | 41.9% | -35.7% | -45.6% | 19.8% | 67.2% | 35.6% | 45.0% | 46.1% | 46.2% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.